Core Insights - Bionano Genomics, Inc. announced a peer-reviewed study demonstrating the effectiveness of optical genome mapping (OGM) in detecting genomic alterations from various gene editing technologies, indicating its potential as a quality control tool for cell-line genome integrity [1][2][3] Group 1: Study Findings - OGM was utilized to analyze human induced pluripotent stem cell (iPSC) lines, showing sensitivity to variant allele fractions (VAFs) as low as 5% [2] - The study revealed that transposons and lentiviral transduction led to a higher number of transgene insertions compared to the more precise CRISPR-Cas9 technology [2] - OGM outperformed traditional methods in detecting complex structural variants (SVs) and revealed previously undetected genomic alterations, suggesting potential pathogenic off-target effects from gene editing [2] Group 2: Industry Implications - OGM is increasingly recognized as a powerful alternative to traditional cytogenetics, particularly in the context of hematologic malignancies and genetic diseases [3] - The integration of OGM as a complementary quality control tool is expected to enhance confidence in the safety and reliability of engineered cell products in therapeutic development pipelines [3] - Bionano's mission is to transform genome analysis through OGM solutions, diagnostic services, and software, aiming to address challenging questions in biology and medicine [4]